when 20 strains representing 9 different nonstaphylococcal species were tested. Some of the non-S. aureus staphylococci produced thermostable nucleases but were PCR negative. The PCR product was generated when in vitro-cultured S. aureus was used to prepare simulated clinical specimens of blood, urine, cerebrospinal fluid, or synovial fluid. No PCR product was generated when the sterile body fluids were tested. However, the sensitivity of the PCR was reduced when S. aureus in blood or urine was tested in comparison with that when bacteria in saline were tested. With the bacteria in blood, the detection limit of the PCR was 103 CFU. A positive PCR result was recorded when a limited number of clinical samples from wounds verified to be infected with S. aureus were tested, while the PCR product was not detected in materials from infections caused by other bacteria. Generation of PCR products was not affected by exposure of S. aureus to bactericidal agents, including cloxacillin and gentamicin, prior to testing, but was affected by exposure to UV radiation. The PCR for amplification of the nuc gene has potential for the rapid diagnosis of S. aureus infections by direct testing of clinical specimens, including specimens from patients with ongoing antimicrobial therapy.
the S. aureus TNase and obtained results which indicated specificity for S. aureus (1) . These results accord with the supposition that the S. aureus TNase has species-specific sequences. This was supported by the findings of Liebl et al. (17) , who used a 518-bp fragment of the cloned S. aureus TNase gene which specifically recognized S. aureus strains in a membrane-based DNA hybridization test.
There are numerous applications of the polymerase chain reaction (PCR) in the diagnosis of infectious diseases (24) . The sensitivity of the PCR method enables the direct detection of low concentrations of bacteria or bacterial products in clinical materials (3, 5, 7, (27) (28) (29) 32) . In the present study, we took advantage of the apparently unique sequences of the S. aureus TNase and applied the PCR for the amplification of a sequence of the nuc gene by using two primers that targeted this gene.
MATERIALS AND METHODS
Strains and culture conditions. The S. aureus Wood 46 strain was received from P. Oeding, Bergen, Norway. Staphylococcus intermedius, Staphylococcus hyicus, and Staphylococcus schleiferi strains were kindly delivered by T. Wadstrom, Lund, Sweden. American Type Culture Collection (ATCC), Rockville, Md., and Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSM), Braunsch- weig, Germany, strains were purchased from those organizations. All clinical strains were isolated in our laboratory. Clinical staphylococcal and micrococcal strains were identified biochemically by the automated API Staph system (API Systems S.A., Montalieu Vercieu, France), the Staphylase test (Oxoid Diagnostic Reagents, Basingstoke, United King-DETECTION OF S. A UREUS BY PCR dom) and the TNase test as described by Lachica et al. (13) . Nonstaphylococcal clinical strains were identified by the appropriate API systems used routinely in our laboratory. Strains were preserved in Stuart transport medium at -80°C. Single colonies of isolates were cultured on blood agar plates or were inoculated into 1% (wt/vol) glucose broth and incubated at 37°C for 18 h. Oligonucleotide probes. Primers were selected on the basis of the published nucleotide sequence of the 966-bp nuc gene derived from the S. aureus Foggi strain (23) . Several primers were synthesized on a System 200 A DNA synthesizer (Beckman Instruments Inc., Palo Alto, Calif.), vacuum dried, and stored at -20°C in double-distilled water. Two primers were selected after checking for self-complementarity. The sequences of the two primers of 21 and 24 bases, respectively, were 5'-GCGATTGATGGTGATACGGTI-3' (primer 1) and 5'-AGCCAAGCCTTGACGAACTAAAGC-3' (primer 2). The primers were located within the 447-bp nuc A gene, which encodes the nuclease A (23); primer 1 was between nucleotides +48 and +70, and primer 2 was between nucleotides +303 and +328. The primers were used without further purification.
For hybridization studies, a 33-mer probe with the sequence 5'-GGTGTAGAGAAATATGGTCCTGAAGCAAG TGCA-3' was used; the sequence corresponds to the nucleotides between positions + 147 and + 181 of the nuc A gene (23) .
Preparation of bacteria for PCR. Broth cultures of bacteria were diluted in presterilized saline prior to lysis and amplification by PCR. For measuring the sensitivity of the PCR, 10-fold serial dilutions (105 to 0 bacteria per ml in saline) were tested. Specificiti studies were performed by testing various bacteria (=10 bacteria per ml). In these experiments, 100 p.l of the diluted suspension (z100 bacteria) was pelleted at 12,000 x g for 15 2 ,000 x g for 5 min. The supernatants (1 ml) were pelleted (12,000 x g; 15 min), the pellets were resuspended in 1 x PCR buffer and centrifuged (12,000 x g; 15 min), and the final pellets were suspended in 100 p.l of lysis buffer. The cells were then lysed as described above. Other body fluids (100 p.l) were diluted in 0.9 ml of lx PCR buffer without saponin, pelleted, washed, and suspended in the lysis buffer as described above for the blood samples.
Clinical specimens on cotton swabs from wounds verified to be infected with S. aureus were examined. The swabs were agitated on a whirl mixer in 5 ml of sterile saline, and 100 p.l was centrifuged (12, HaeIII DNA digest (Sigma) was used as a DNA marker.
Southern blot analysis. PCR products were separated on a 1.3% agarose gel and transferred to a Zeta Probe blotting membrane (Bio-Rad) essentially as described by Sambrook et al. (22) , but the depurination step was omitted. The membrane was fixed under UV light on a transilluminator (5 ratio, and DNA concentrations were estimated by measuring the optical density at 260 nm (4) .
RESULTS
The primer set synthesized for this study allowed PCR amplification of a gene fragment when S. aureus strains were lysed and amplified by 35, 37, or 40 cycles. We found that 37 cycles was optimal. Increases in the annealing time from 0.5 to 2 min and the primer extension time from 1.5 to 2 min did not increase the sensitivity of the method. Figure 1 shows the results obtained when some reference strains of S. aureus and non-S. aureus staphylococci were tested in the PCR. The S. aureus strains were amplified, while the non-S. aureus strains were not. The PCR product appeared as a single DNA band with a size close to that of the 267-bp band of the pBR322 HaeIII DNA digest (Fig. 1A) . This size is close to the expected size of 279 bp for the PCR product. Repeat testing of some of the strains that we examined showed the same results. A 33-mer DNA probe corresponding to a nuc gene sequence located between the sites of the two primers hybridized to the PCR products by Southern blot analysis (Fig. 1B) . This finding confirmed the nuc gene origin of the amplified products.
Sensitivity. The lower limit for detection of S. aureus bacterial cells or isolated DNA by PCR was examined. A suspension of S. aureus Foggi was diluted in saline, and the bacteria were counted by epifluorescence microscopy and CFU determination. Amplification which resulted in detectable levels of PCR product was achieved when a minimum of 6 CFU of S. aureus cells were lysed; this corresponded to 14 cells determined by epifluorescence microscopy ( Fig. 2A) . By repeat testing of viable S. aureus cells, the detection limit ranged from 5 to 20 CFU. Similar detection limits were observed when other S. aureus strains (Wood 46 and V8) were examined. DNA from S. aureus Foggi was isolated, serially diluted in saline, and used as a template. The results show (Fig. 2B) no bacteria added, none of the biological fluids gave rise to amplification products. The sensitivity of the PCR was examined with S. aureus serially diluted in the various body fluids. With the bacteria in the cerebrospinal or synovial fluid, the lower detection limit ranged from 10 to 20 CFU, which was similar to the limit recorded with bacteria in saline. However, with S. aureus in urine, the lower detection limit was 100 CFU, and in whole blood it was 1,000 CFU. A total of 29 clinical samples collected on cotton swabs from patients with verified wound infections caused by S. aureus (n = 19) or other bacteria (n = 10) were tested by the PCR. The results for some of these samples are shown in Fig. 4 . All of the samples which grew S. aureus gave rise to a positive PCR result with bands of the expected size, but none of the samples which grew other bacteria gave rise to a positive PCR result. The intensities of the bands varied. Weak bands were recorded from samples with a low number of S. aureus or materials admixed with large quantities of blood (data not shown). For two of the non-S. aureus samples (Klebsiella pneumoniae and Eschenchia coli), weak bands (=500 bp) could be visualized (Fig. 4, lane 11) .
PCR with bacteria exposed to antimicrobial agents. To analyze whether S. aureus Foggi cells exposed to bactericidal agents were amplified, the bacteria (107 bacterial cells) were exposed to cloxacillin or gentamicin at concentrations above the MICs for the bacteria, UV irradiation, formaldehyde, or ethanol. Exposure to antimicrobial agents resulted in a >99% CFU reduction; exposure to the other agents resulted in 100% CFU reduction. The irradiation totally inhibited the PCR amplification when =100 bacterial cells were tested. The other agents had no effect on the gene product observed after electrophoresis. templates for the primers, each with =100 bacterial cells in the PCR mixture. All of the S. aureus strains were amplified and were thus recognized by the primers, but none of the other staphylococci were amplified or recognized by the primers ( Table 1 ). The enzymatic test for TNase activity was positive with all of the S. aureus strains and with 14 of the non-S. aureus strains, with all of the non-S. aureus strains belonging to the species S. intennedius, S. hyicus, or S. schleiferi (Table 1 ). The specificity of the primer set was also examined by testing a total of 156 clinical isolates of various bacteria, including 83 S. aureus strains ( Table 2) . Only the S. aureus strains were recognized by the primer set and amplified. With all of the S. aureus isolates examined, a PCR product of approximately 270 bp was generated. Of the non-S. aureus clinical staphylococcal strains (n = 53), three S. schleifeni strains showed TNase activity but were PCR negative ( Table 2) .
PCR of body fluids. For PCR analysis of clinical specimens, biological materials should not interfere with the reaction. Culture-negative whole blood, urine, synovial fluid, and cerebrospinal fluid were tested with and without in vitro-cultured S. aureus Foggi bacteria added (=1,000 bacteria in the reaction mixture) (Fig. 3) . All of the samples which contained bacteria were amplified. When tested with Nucleic acid amplification by PCR has applications in many fields of biology and medicine, including the detection of viruses, bacteria, and other infectious agents (for a review and references, see reference 24). In the present study, we synthesized an oligonucleotide primer set which recognized sequences of the S. aureus nuc gene, which encodes the TNase produced by these bacteria. This strategy was chosen since earlier data obtained by using polyclonal (6, 15) or monoclonal (1) antibodies to detect the S. aureus TNase indicated that this protein has species-specific sequences and that DNA hybridization-based methods corroborated the assumption that this protein is species specific (17) . On the other hand, some non-S. aureus staphylococci, streptococci, and possibly other bacteria (6) may produce nucleases with enzymatic activity that mimics that of the S. aureus TNase.
A simple method of lysing the bacteria was applied in this study. The primer set determined the generation of a PCR product of approximately 270 bp, which is close to the expected gene fragment size of 279 bp (23) . A 33-mer DNA probe, corresponding to an internal sequence of the 270-bp segment, hybridized with the PCR products. This confirmed that the product is identical to a sequence of the S. aureus nuc gene.
Strict precautions must be taken to avoid false-positive PCR results because of amplification of contaminating DNA (12) . Early in our experiments, we were confronted with this problem; we eliminated contaminating DNA by irradiating all the equipment used in the preamplification steps with UV light, in accordance with the precautions recommended by others (20) and with our own results, which confirmed that VOL. 30, 1992 on November 6, 2017 by guest http://jcm.asm.org/ Downloaded from UV irradiation of S. aureus eliminates the generation of a PCR product. The nuc PCR detected <20 viable S. aureus cells or correspondingly low levels (0.69 pg) of extracted DNA in saline. The sensitivity accords with that described for PCR with other bacteria, being between 1 and 20 CFU (16, 19, 29, 32) or between 1 and 100 pg for DNA extracted from S. aureus (8, 35) . An increase in sensitivity may be achieved by nested PCR amplification (35) .
The nuc primer set recognized all staphylococci identified 6) (25) and of genes encoding toxins, such as the exfoliative toxins, toxic shock syndrome toxins, and enterotoxins (8, 35) , which are produced by many S. aureus isolates. Recently, PCR amplification of the nuc gene was reported by Wilson et al. (35) , who used a primer set different from that used in the present study. Those investigators amplified a 450-bp segment of the gene. However, very few data of this amplification were described (35) . The combination of the nuc PCR for species identification of S. aureus and PCRs for the identification of genes encoding defined phenotypic characteristics of the bacteria is therefore possible.
DNA amplification by PCR has applicability in the diagnosis of infectious diseases, provided that the tests have adequate sensitivity and specificity. For instance, this method was equivalent to culture with respect to the detection of Haemophilus influenzae in cerebrospinal fluid (29) , Chlamydia trachomatis in various clinical specimens (3) , and Borrelia burgdorfen in clinical material from experimentally infected animals (16). The sterile body fluids which we tested in the S. aureus nuc PCR-blood, synovial fluid, urine, and cerebrospinal fluid-were negative in the test, whereas positive test results were recorded provided that S. aureus was added to produce simulated culture-positive clinical specimens. However, with bacteria in urine, and notably with bacteria in blood, the sensitivity of the nuc PCR was far lower than that with bacteria in saline. With bacteria in blood, the lower detection limit was higher than the number of CFU per unit volume of blood, which usually is found in patients with bacteremia (10) . We added saponin to the blood since this is reported to lyse phagocytes and to release phagocytosed bacteria (33) . By this treatment we also anticipated removal of most of the hemoglobin, which is known to interfere with the PCR (34) . The reduced sensitivity of the nuc PCR for detection of S. aureus in blood may be due to residual interfering components.
All of the 19 swab specimens which contained S. aureus were positive by direct testing in the nuc PCR for the 270-bp PCR product, whereas all specimens which grew other bacteria were negative. These findings substantiate the prospects of the rapid diagnosis of S. aureus infections by the nuc PCR described in this report, for instance, when a rapid diagnosis is important in order to initiate adequate therapy immediately or when ongoing therapy interferes with the in vitro growth of the bacteria. Our data indicate that treatment with antibiotics does not interfere with the detection of the nuc gene as long as sufficient quantities of the target DNA sequences are still present in the clinical specimens. We observed that the quantity of the 270-bp PCR product varied with the number of S. aureus CFU isolated from the specimen. Lebech et al. (16) reported that extraction of DNA is needed when actual clinical specimens instead of simulated specimens are tested. This method and other techniques that may increase the sensitivity of the nuc PCR for the detection of S. aureus in clinical specimens need to be investigated further. Notably, methodological improvements are required to increase the sensitivity of the test for the rapid detection of S. aureus bacteremia, since this is a particularly important clinical situation for application of the test.
Also, the nuc PCR may be applicable for testing nonclinical samples like food or as a research tool, for instance, in studies of the distribution and fate of S. aureus in various organs and cells of the body.
